RESEARCH TRIANGLE PARK – BioSkryb Genomics, a Durham developer of amplification tools for single-cell analysis, has signed an agreement with a Dutch company to expand distribution of BioSkryb’s genomic and multiomic technology in Europe.
The agreement with Bioke, a distributor of life sciences technology and products, gives BioSkryb a presence in seven countries: Belgium, Denmark, Finland, Luxembourg, the Netherlands, Norway and Sweden. BioSkryb develops comprehensive single-cell multiomic research products used in cancer research and other applications in precision medicine.
The companies didn’t disclose financial terms.
“Our technology allows for a deeper understanding of the cellular ecosystem and has the potential to transform the way researchers and clinicians understand and treat devastating diseases, such as cancer,” said Suresh Pisharody, BioSkryb’s CEO. “We are excited to work closely with the Bioke team to bring our powerful solutions to a broader network of researchers in the European market.”
BioSkryb produces an advanced set of research tools based on Primary Template-directed Amplification (PTA) technology. The company’s products give researchers the ability to better understand the genome, transcriptome and proteome within a single cell. As a result, researchers can get a more complete picture of what drives complex disease.
The Bioke agreement gives BioSkryb additional distribution of its leading products, including ResolveDNA, a whole genome amplification kit that reproduces genomes of single cells, and ResolveOME, a whole genome and transcriptome amplification kit. The company commercially launched ResolveOME in February along with a bioinformatics platform called BaseJumper.
BioSkryb got its start in 2018 by licensing PTA technology from the St. Jude Children’s Research Hospital team that developed it, led by Charles Gawad, MD, PhD, who co-founded BioSkryb and continues to serve as a director and member of its scientific advisory board. Gawad is an associate professor of pediatrics at Stanford University.
In January 2020, the company secured a seed round of $11.5 million in funding. Anzu Partners, a venture capital firm in Washington, led the round with participation from law firm Wilson Sonsini Goodrich & Rosati.
About 40 of BioSkryb’s 65 employees are at its Meridian Parkway headquarters.
(C) N.C. Biotech Center